Biotech Early Movers: OncoGenex Pharmaceuticals Inc(NASDAQ:OGXI), Agenus Inc(NASDAQ:AGEN), Athersys, Inc.(NASDAQ:ATHX)

OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) shares plunged more than 48% pre-market after the company said results from its Phase 3 SYNERGY trial to add custirsen to standard first-line treatment of docetaxel/prednisone in men with metastatic prostate cancer failed to meet primary endpoints. The stock which was halted from trading ahead of the news, recently changed hands at $5.00, off an earlier low of $4.25. The shares … Continue reading Biotech Early Movers: OncoGenex Pharmaceuticals Inc(NASDAQ:OGXI), Agenus Inc(NASDAQ:AGEN), Athersys, Inc.(NASDAQ:ATHX)

Neptune Technologies & Bioressources-Ord (NASDAQ:NEPT) and Enzymotec Ltd (NASDAQ:ENZY) Conclude Final Patent Infringement Settlement

Neptune Technologies & Bioressources-Ord (NASDAQ:NEPT) and Acasti Pharma Inc (NASDAQ:ACST), a Neptune subsidiary, Sunday night announced that a final and binding patent infringement settlement and license agreement has been signed with Enzymotec Ltd. and Enzymotec Ltd(NASDAQ:ENZY) that resolves the International Trade Commission’s investigation of infringement of Neptune’s composition of matter patents, related federal court actions initiated by Neptune against Enzymotec and its distributors, and various patent review … Continue reading Neptune Technologies & Bioressources-Ord (NASDAQ:NEPT) and Enzymotec Ltd (NASDAQ:ENZY) Conclude Final Patent Infringement Settlement

Biotech Pre-Market Movers: Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA), Synergy Pharmaceuticals Inc(NASDAQ:SGYP), Pfizer Inc.(NYSE:PFE), AstraZeneca plc (ADR)(NYSE:AZN)

The American Despositary Receipts of Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA) edged up in recent pre-market trading on Monday after announcing over the weekend an agreement it has signed with Takeda Pharmaceutical for the marketing and sale of Rasagiline in Japan. Rasagiline is a treatment for Parkinson’s Disease developed by TEVA and has been approved in over 40 countries. TEVA closed at $48.69 on Friday in … Continue reading Biotech Pre-Market Movers: Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA), Synergy Pharmaceuticals Inc(NASDAQ:SGYP), Pfizer Inc.(NYSE:PFE), AstraZeneca plc (ADR)(NYSE:AZN)

AstraZeneca plc (ADR)(NYSE:AZN) Shares Soar Pre-Market

Shares of AstraZeneca plc (ADR)(NYSE:AZN) reached a new high in pre-market trading as Pfizer Inc.(NYSE:PFE) confirmed it has attempted to renew negotiations on a possible merger. Pfizer submitted a preliminary indication of interest to the board of directors of AstraZeneca in January 2014 regarding the possible merger. AstraZeneca declined to pursue negotiations at that time, but Pfizer contacted AstraZeneca on April 26, 2014, seeking to renew … Continue reading AstraZeneca plc (ADR)(NYSE:AZN) Shares Soar Pre-Market

Sonic Beats on Q2 Earnings, In Line on Revenue

Sonic (NASDAQ:SONC) reported Q2 earnings of $0.07 per share, up from $0.05 per share last year and a penny better than the analyst consensus on Capital IQ. System-wide same-store sales increased 1.4%, consisting of an increase of 1.5% at franchise drive-ins and an increase of 1.3% at company drive-ins. Total revenue was $109.7 million, down from $111.1 million last year and about in line with … Continue reading Sonic Beats on Q2 Earnings, In Line on Revenue

Biotech Volatile Stocks: CytRx Corporation (NASDAQ:CYTR), Synta Pharmaceuticals (NASDAQ:SNTA), Idenix Pharmaceuticals (NASDAQ:IDIX), CEL-SCI Corporation (NYSEMKT:CVM)

Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of purchasers of CytRx Corporation (NASDAQ:CYTR) common stock during the period between November 22, 2013 and March 13, 2014, inclusive (the “Class Period”). CytRx Corporation (NASDAQ:CYTR) stock performance was 0.00% in last session and finished the day … Continue reading Biotech Volatile Stocks: CytRx Corporation (NASDAQ:CYTR), Synta Pharmaceuticals (NASDAQ:SNTA), Idenix Pharmaceuticals (NASDAQ:IDIX), CEL-SCI Corporation (NYSEMKT:CVM)